Role of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy

Hussain, Nazimul; Hussain, Anjli; Natarajan, Sundaram

doi:10.4103/0301-4738.16172

Cited by 29 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several therapeutic procedures are used to treat PCV, including photodynamic therapy (PDT) and intravitreal injections of anti-vascular endothelial growth factor (VEGF). Patients with PCV generally respond well to PDT; [2][3][4][5][6][7][8][9][10][11] however, the vascular network often persists and causes recurrences, 10,12 which prevent good visual recovery. Therefore, reducing the number of recurrences is an important aspect of the treatment of PCV.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy

Oishi

Mandai

Kimakura

et al. 2011

Eye

View full text Add to dashboard Cite

Objective To characterize an irregular capillary-like structure in the vascular network of eyes with polypoidal choroidal vasculopathy (PCV), and to determine whether its presence after photodynamic therapy (PDT) can be used to predict the clinical course of PCV. Methods We reviewed the clinical records of 29 eyes of 29 patients with PCV, who underwent PDT and confocal retinal angiographic examinations every 3 months. The images obtained before the PDT were compared with those after the PDT. The correlations between angiography findings and recurrences were evaluated. Results An area of fine, densely packed capillary-like vessels, named the fine vascular network, was identified within the polypoidal vascular network in 25 of 29 cases at the initial examination. The fine vascular network regressed in 23 cases (92%) after the first PDT. Thereafter, the fine vascular network remained or enlarged in 19 eyes, and 17 (84.5%) of these eyes had a recurrence of the polypoidal lesions or had exudative changes. In contrast, recurrences were found in only 2 of 10 (20%) eyes, whose fine network had regressed without a subsequent enlargement (Po0.001 compared with the former group). Conclusions A fine irregular vascular network is present in the majority of eyes with PCV before PDT. Its presence or expansion after PDT was significantly associated with a recurrence of PCV. Thus, we recommend that this network be monitored after treatment to determine whether a polypoidal vascular network will recur.

show abstract

Section: Introductionmentioning

confidence: 99%

Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy

Oishi

Mandai

Kimakura

et al. 2011

Eye

View full text Add to dashboard Cite

show abstract

“…Polypoidal choroidal vasculopathy (PCV) is a chronic condition with history of repeated recurrences of spontaneous leakage or haemorrhage at the macula which may closely mimic recurrent CSR [6]. Following ICG angiography, the abnormal choroidal vasculature can be precisely demarcated and treated with photodynamic therapy (PDT) or TTT.…”

Section: Discussionmentioning

confidence: 99%

Role of Transpupillary Thermotherapy in Central Serous Chorio-Retinopathy

Mathur

Parihar

Maggon

et al. 2009

Medical Journal Armed Forces India

View full text Add to dashboard Cite

“…[16][17][18][19][20][21] In a case series of 22 eyes in 21 Chinese patients with PCV reported by Chan et al, 16 95% of eyes achieved stable or improved vision and 45% of eyes had improvement of X3 lines at 1 year follow-up. Unfortunately, we were unable to mirror these excellent results as in our series of 41 eyes in 40 Asian patients with a mean follow-up of almost 2 years, only 24 eyes (58.5%) achieved stable or improved vision.…”

Section: Discussionmentioning

confidence: 99%

“…[16][17][18][19][20][21] The majority of these studies have reported evidence of a beneficial effect with PDT. In our study, we report the outcomes of patients with symptomatic PCV treated with PDT with verteporfin after a mean follow-up of almost 2 years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy

Wong

et al. 2008

Eye

View full text Add to dashboard Cite

Background To describe the efficacy of photodynamic therapy (PDT) with verteporfin for the treatment of polypoidal choroidal vasculopathy (PCV). Methods This is a retrospective interventional case series of 41 eyes of 40 patients with angiographic evidence of PCV, which had PDT with verteporfin. Pre-treatment best-corrected visual acuity (BCVA) was measured and patients were followed up for at least 12 months with BCVA recorded at each visit. Results The mean follow-up time was 23.7 months. Seven of 10 eyes (70%) with juxtafoveal lesions and 17 of 31 eyes (54.8%) with subfoveal lesions had stable or improved vision (loss of p3 lines) at the last follow-up. The mean number of treatments was 1.90. Thirty-three eyes (80.5%) had dry, quiescent scars at last follow-up, six eyes (14.6%) had persistent leakage, and two eyes (4.9%) had evidence of choroidal neovascularisation. Conclusion Our results indicate that 24 of 41 eyes (58.5%) with serosanguinous maculopathy secondary to PCV treated with PDT had stable or improved vision (loss of p3 lines) after a mean follow-up of almost 2 years. However, in view of the retrospective nature of this study, the true efficacy of PDT for PCV would have to be evaluated with a larger randomised controlled trial.

show abstract

Role of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy

Cited by 29 publications

References 0 publications

Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy

Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy

Role of Transpupillary Thermotherapy in Central Serous Chorio-Retinopathy

Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy

Contact Info

Product

Resources

About